The role of lanreotide Autogel^® in the treatment of acromegaly

References

• Kane LA, Leinung MC, Scheithauer BW et al. Pituitary adenomas in childhood and adolescence. J. Clin. Endocrinol. Metab.79(4), 1135–1140 (1994).
   PubMed Web of Science ®Google Scholar
• Mukai K, Seljeskog EL, Dehner LP. Pituitary adenomas in patients under 20 years old. A clinicopathological study of 12 cases. J. Neurooncol.4(1), 79–89 (1986).
   Google Scholar
• Jagannathan J, Dumont AS, Prevedello DM et al. Genetics of pituitary adenomas: current theories and future implications. Neurosurg. Focus19(5), E4 (2005).
   Google Scholar
• Salehi F, Cohen S, Syro LV et al. Plurihormonality in pituitary adenomas associated with acromegaly. Endocr. Pathol.17(3), 291–296 (2006).
   Google Scholar
• Lamberts SW, Klijn JG, van Vroonhoven CC, Stefanko SZ, Liuzzi A. The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly. Acta Endocrinol. (Copenh.)103(4), 446–450 (1983).
   Google Scholar
• Andersen M, Hansen TB, Bollerslev J, Bjerre P, Schrøder HD, Hagen C. Effect of 4 weeks of octreotide treatment on prolactin, thyroid stimulating hormone and thyroid hormones in acromegalic patients. A double blind placebo-controlled cross-over study. J. Endocrinol. Invest.18, 840–846 (1995).
   Google Scholar
• Abs R, Verhelst J, Maiter D et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J. Clin. Endocrinol. Metab.83(2), 374–378 (1998).
   PubMed Web of Science ®Google Scholar
• Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin. Endocrinol. (Oxf.)61(2), 209–215 (2004).
   PubMed Web of Science ®Google Scholar
• Mestron A, Webb SM, Astorga R et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur. J. Endocrinol.151(4), 439–446 (2004).
   PubMed Web of Science ®Google Scholar
• Bengtsson BA, Eden S, Ernest I, Oden A, Sjogren B. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med. Scand.223, 327–335 (1988).
   PubMed Web of Science ®Google Scholar
• Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clin. Endocrinol. (Oxf.)12(1), 71–79 (1980).
   PubMed Web of Science ®Google Scholar
• Etxabe J, Gaztambide S, Latorre P, Vazquez JA. Acromegaly: an epidemiological study. J. Endocrinol. Invest.16(3), 181–187 (1993).
   PubMed Web of Science ®Google Scholar
• Ritchie CM, Atkinson AB, Kennedy AL et al. Ascertainment and natural history of treated acromegaly in Northern Ireland. Ulster Med. J.59(1), 55–62 (1990).
   PubMedGoogle Scholar
• Melmed S. Medical progress: acromegaly. N. Engl. J. Med.355(24), 2558–2573 (2006).
   PubMed Web of Science ®Google Scholar
• Andersen M, Hagen C, Frystyk J, Schroeder HD, Hagen C. Development of acromegaly in patients with prolactinomas. Eur. J. Endocrinol.149(1), 17–22 (2003).
   PubMed Web of Science ®Google Scholar
• Sakharova AA, Dimaraki EV, Chandler WF, Barkan AL. Clinically silent somatotropinomas may be biochemically active. J. Clin. Endocrinol. Metab.90(4), 2117–2121 (2005).
   PubMedGoogle Scholar
• Clemmons DR. Clinical utility of measurements of insulin-like growth factor 1. Nat. Clin. Pract. Endocrinol. Metab.2(8), 436–446 (2006).
   PubMedGoogle Scholar
• Giustina A, Barkan A, Casanueva FF et al. Criteria for cure of acromegaly: a consensus statement. J. Clin. Endocrinol. Metab.85(2), 526–529 (2000).
   PubMed Web of Science ®Google Scholar
• Baumann G. Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins. Endocr. Rev.12(4), 424–449 (1991).
   PubMed Web of Science ®Google Scholar
• Baumann G, Stolar MW. Molecular forms of human growth hormone secreted in vivo: nonspecificity of secretory stimuli. J. Clin. Endocrinol. Metab.62(4), 789–790 (1986).
   Google Scholar
• Baumann G, Stolar MW, Amburn K. Molecular forms of circulating growth hormone during spontaneous secretory episodes and in the basal state. J. Clin. Endocrinol. Metab.60(6), 1216–1220 (1985).
   Google Scholar
• Jansson C, Boguszewski C, Rosberg S, Carlsson L, Albertsson-Wikland K. Growth hormone (GH) assays: influence of standard preparations, GH isoforms, assay characteristics, and GH-binding protein. Clin. Chem.43(6 Pt 1), 950–956 (1997).
   PubMedGoogle Scholar
• Andersen M, Petersen PH, Blaabjerg O, Hangaard J, Hagen C. Evaluation of growth hormone assays using ratio plots. Clin. Chem.44(5), 1032–1038 (1998).
   Google Scholar
• Leung KC, Howe C, Gui LY, Trout G, Veldhuis JD, Ho KK. Physiological and pharmacological regulation of 20-kDa growth hormone. Am. J. Physiol. Endocrinol. Metab283(4), E836–E843 (2002).
   Google Scholar
• Ronchi CL, Arosio M, Rizzo E, Lania AG, Beck-Peccoz P, Spada A. Adequacy of current postglucose GH nadir limit (<1 microg/l) to define long-lasting remission of acromegalic disease. Clin. Endocrinol. (Oxf.)66(4), 538–542 (2007).
   Google Scholar
• Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE, Post KD. Significance of “abnormal” nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J. Clin. Endocrinol. Metab.89(2), 495–500 (2004).
   PubMed Web of Science ®Google Scholar
• Dimaraki EV, Jaffe CA, Mott-Friberg R, Chandler WF, Barkan AL. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J. Clin. Endocrinol. Metab.87(8), 3537–3542 (2002).
   PubMed Web of Science ®Google Scholar
• Puder JJ, Nilavar S, Post KD, Freda PU. Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J. Clin. Endocrinol. Metab.90(4), 1972–1978 (2005).
   Google Scholar
• Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev.16(1), 3–34 (1995).
   PubMed Web of Science ®Google Scholar
• Daughaday WH, Kapadia M, Mariz I. Serum somatomedin binding proteins: physiologic significance and interference in radioligand assay. J. Lab. Clin. Med.109(3), 355–363 (1987).
   PubMed Web of Science ®Google Scholar
• Juul A. Determination of insulin-like growth factor I in children: normal values and clinical use. Horm. Res.55(Suppl. 2), 94–99 (2001).
   Google Scholar
• Clemmons DR. Commercial assays available for insulin-like growth factor I and their use in diagnosing growth hormone deficiency. Horm. Res.55(Suppl. 2), 73–79 (2001).
   PubMedGoogle Scholar
• Melmed S. Mechanisms for pituitary tumorigenesis: the plastic pituitary. J. Clin. Invest.112(11), 1603–1618 (2003).
   PubMed Web of Science ®Google Scholar
• Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune–Albright syndrome. N. Engl. J. Med.325(24), 1688–1695 (1991).
   PubMed Web of Science ®Google Scholar
• Vallar L, Spada A, Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature330(6148), 566–568 (1987).
   PubMed Web of Science ®Google Scholar
• Ludecke DK, Abe T. Transsphenoidal microsurgery for newly diagnosed acromegaly: a personal view after more than 1,000 operations. Neuroendocrinology83(3–4), 230–239 (2006).
   PubMed Web of Science ®Google Scholar
• Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. Eur. J. Endocrinol.152(3), 379–387 (2005).
   PubMed Web of Science ®Google Scholar
• Grottoli S, Celleno R, Gasco V et al. Efficacy and safety of 48 weeks of treatment with octreotide LAR in newly diagnosed acromegalic patients with macroadenomas: an open-label, multicenter, non-comparative study. J. Endocrinol. Invest.28(11), 978–983 (2005).
   PubMed Web of Science ®Google Scholar
• Cozzi R, Montini M, Attanasio R et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J. Clin. Endocrinol. Metab.91(4), 1397–1403 (2006).
   PubMed Web of Science ®Google Scholar
• Mercado M, Borges F, Bouterfa H et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin. Endocrinol. (Oxf.)66(6), 859–868 (2007).
   PubMed Web of Science ®Google Scholar
• Colao A, Pivonello R, Rosato F et al. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin. Endocrinol. (Oxf.)64(3), 342–351 (2006).
   PubMed Web of Science ®Google Scholar
• Lucas T, Astorga R, Catala M. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clin. Endocrinol. (Oxf.)58(4), 471–481 (2003).
   PubMed Web of Science ®Google Scholar
• Colao A, Attanasio R, Pivonello R et al. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J. Clin. Endocrinol. Metab.91(1), 85–92 (2006).
   PubMed Web of Science ®Google Scholar
• Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J. Clin. Endocrinol. Metab.89(4), 1613–1617 (2004).
   PubMed Web of Science ®Google Scholar
• Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J. Clin. Endocrinol. Metab.83(8), 2730–2734 (1998).
   PubMed Web of Science ®Google Scholar
• Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab.89(2), 667–674 (2004).
   PubMed Web of Science ®Google Scholar
• Biermasz NR, Dekker FW, Pereira AM et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J. Clin. Endocrinol. Metab.89(6), 2789–2796 (2004).
   PubMed Web of Science ®Google Scholar
• Monson JP. Is there still a role for radiotherapy in acromegaly? Neuroendocrinology83(3–4), 269–273 (2006).
   Google Scholar
• Minniti G, Traish D, Ashley S, Gonsalves A, Brada M. Fractionated stereotactic conformal radiotherapy for secreting and nonsecreting pituitary adenomas. Clin. Endocrinol. (Oxf.)64(5), 542–548 (2006).
   PubMedGoogle Scholar
• Sheehan JP, Jagannathan J, Pouratian N, Steiner L. Stereotactic radiosurgery for pituitary adenomas: a review of the literature and our experience. Front Horm. Res.34, 185–205 (2006).
   PubMed Web of Science ®Google Scholar
• Tomlinson JW, Holden N, Hills RK et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet357(9254), 425–431 (2001).
   PubMed Web of Science ®Google Scholar
• Biermasz NR, van Thiel SW, Pereira AM et al. Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J. Clin. Endocrinol. Metab.89(11), 5369–5376 (2004).
   PubMed Web of Science ®Google Scholar
• Rowles SV, Prieto L, Badia X, Shalet SM, Webb SM, Trainer PJ. Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. J. Clin. Endocrinol. Metab.90(6), 3337–3341 (2005).
   PubMed Web of Science ®Google Scholar
• Kauppinen-Makelin R, Sane T, Sintonen H et al. Quality of life in treated patients with acromegaly. J. Clin. Endocrinol. Metab.91(10), 3891–3896 (2006).
   Google Scholar
• Webb SM. Quality of life in acromegaly. Neuroendocrinology83(3–4), 224–229 (2006).
   PubMed Web of Science ®Google Scholar
• Burt MG, Ho KK. Newer options in the management of acromegaly. Intern. Med. J.36(7), 437–444 (2006).
   PubMed Web of Science ®Google Scholar
• Gatta B, Hau DH, Catargi B, Roger P, Tabarin A. Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients. Clin. Endocrinol. (Oxf.)63(4), 477–478 (2005).
   PubMed Web of Science ®Google Scholar
• Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, Wells JA. Rational design of potent antagonists to the human growth hormone receptor. Science256(5064), 1677–1680 (1992).
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Hutson RK, Trainer PJ et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet358(9295), 1754–1759 (2001).
   PubMed Web of Science ®Google Scholar
• Besser GM, Burman P, Daly AF. Predictors and rates of treatment-resistant tumor growth in acromegaly. Eur. J. Endocrinol.153(2), 187–193 (2005).
   PubMed Web of Science ®Google Scholar
• Lindberg-Larsen R, Moller N, Schmitz O et al. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. J. Clin. Endocrinol. Metab.92(5), 1724–1728 (2007).
   Google Scholar
• Feenstra J, de Herder WW, ten Have SM et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet365(9471), 1644–1646 (2005).
   PubMed Web of Science ®Google Scholar
• Jorgensen JO, Feldt-Rasmussen U, Frystyk J et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J. Clin. Endocrinol. Metab.90(10), 5627–5631 (2005).
   PubMed Web of Science ®Google Scholar
• Vitale G, Pivonello R, Ferone D et al. The role of somatostatin receptors in the medical treatment of acromegaly. Dig. Liver Dis.36(Suppl. 1), S55–S59 (2004).
   Google Scholar
• Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N. Engl. J. Med.334, 246–254 (1996).
   PubMed Web of Science ®Google Scholar
• van der Hoek J, Lamberts SW, Hofland LJ. Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas. Eur. J. Endocrinol.156(Suppl. 1), S45–S51 (2007).
   PubMed Web of Science ®Google Scholar
• Heron I, Thomas F, Dero M et al. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J. Clin. Endocrinol. Metab.76(3), 721–727 (1993).
   PubMed Web of Science ®Google Scholar
• Lancranjan I, Bruns C, Grass P et al. Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism45(8 Suppl. 1), 67–71 (1996).
   PubMed Web of Science ®Google Scholar
• Cozzi R, Dallabonzana D, Attanasio R, Barausse M, Oppizzi G. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly. Eur. J. Endocrinol.141(3), 267–271 (1999).
   PubMed Web of Science ®Google Scholar
• Turner HE, Vadivale A, Keenan J, Wass JA. A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clin. Endocrinol. (Oxf.)51(3), 275–280 (1999).
   PubMed Web of Science ®Google Scholar
• Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab.90(8), 4465–4473 (2005).
   PubMed Web of Science ®Google Scholar
• Flogstad AK, Halse J, Haldorsen T et al. Sandostatin LAR in acromegalic patients: a dose–range study. J. Clin. Endocrinol. Metab.80(12), 3601–3607 (1995).
   Google Scholar
• Antonijoan RM, Barbanoj MJ, Cordero JA et al. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. J. Pharm. Pharmacol.56(4), 471–476 (2004).
   PubMed Web of Science ®Google Scholar
• Lucas T, Astorga R. Efficacy of lanreotide Autogel administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a Phase III trial. Clin. Endocrinol. (Oxf.)65(3), 320–326 (2006).
   PubMed Web of Science ®Google Scholar
• Saveanu A, Gunz G, Dufour H et al. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J. Clin. Endocrinol. Metab.86(1), 140–145 (2001).
   PubMed Web of Science ®Google Scholar
• Bronstein MD. Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome. Front. Horm. Res.35, 129–134 (2006).
   PubMed Web of Science ®Google Scholar
• Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr. Rev.24(1), 28–47 (2003).
   PubMed Web of Science ®Google Scholar
• Cendros JM, Peraire C, Troconiz IF, Obach R. Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel. Metabolism54(10), 1276–1281 (2005).
   PubMed Web of Science ®Google Scholar
• Bronstein M, Musolino N, Jallad R et al. Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clin. Endocrinol. (Oxf.)63(5), 514–519 (2005).
   PubMed Web of Science ®Google Scholar
• Caron P, Cogne M, Raingeard I, Bex-Bachellerie V, Kuhn JM. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin. Endocrinol. (Oxf.)64(2), 209–214 (2006).
   PubMed Web of Science ®Google Scholar
• Caron P, Beckers A, Cullen DR et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J. Clin. Endocrinol. Metab.87(1), 99–104 (2002).
   PubMed Web of Science ®Google Scholar
• Caron P, Bex M, Cullen DR et al. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin. Endocrinol. (Oxf.)60(6), 734–740 (2004).
   PubMed Web of Science ®Google Scholar
• van Thiel SW, Romijn JA, Biermasz NR et al. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur. J. Endocrinol.150(4), 489–495 (2004).
   PubMed Web of Science ®Google Scholar
• Ashwell SG, Bevan JS, Edwards OM et al. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur. J. Endocrinol.150(4), 473–480 (2004).
   PubMed Web of Science ®Google Scholar
• Alexopoulou O, Abrams P, Verhelst J et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur. J. Endocrinol.151(3), 317–324 (2004).
   PubMed Web of Science ®Google Scholar
• Andersen M, Andries M, Flogstad A, Gram J, Hagen C. Comparable effects of lanreotide Autogel and Sandostatin LAR, a 12 months cross-over study in acromegalic patients. Presented at: 12th International Congress of Endocrinology (ICE). Lisbon, Portugal, 31 August–4 September 2004 (Poster).
   Google Scholar
• Pereira AM, Biermasz NR, Roelfsema F, Romijn JA. Pharmacologic therapies for acromegaly: a review of their effects on glucose metabolism and insulin resistance. Treat. Endocrinol.4(1), 43–53 (2005).
   PubMedGoogle Scholar
• Steffin B, Gutt B, Bidlingmaier M, Dieterle C, Oltmann F, Schopohl J. Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. Eur. J. Endocrinol.155(1), 73–78 (2006).
   PubMed Web of Science ®Google Scholar
• Gutt B, Bidlingmaier M, Kretschmar K, Dieterle C, Steffin B, Schopohl J. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of lanreotide (lanreotide Autogel). Exp. Clin. Endocrinol. Diabetes113(3), 139–144 (2005).
   PubMed Web of Science ®Google Scholar
• Cozzi R, Attanasio R, Montini M et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J. Clin. Endocrinol. Metab.88(7), 3090–3098 (2003).
   PubMed Web of Science ®Google Scholar
• Saveanu A, Gunz G, Guillen S, Dufour H, Culler MD, Jaquet P. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Neuroendocrinology83(3–4), 258–263 (2006).
   PubMed Web of Science ®Google Scholar
• Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N. Engl. J. Med.356(1), 29–38 (2007).
   PubMed Web of Science ®Google Scholar